National Kidney Month
I’d never given much thought to kidneys — mine or anyone else’s — until I found myself in the care of an infusion nurse who’d given one of her kidneys to her sister while in college.
I listened intently as my nurse told me about first losing her brother to kidney failure and then doing her part to save her sister, who has the same genetic disease.
I considered how I’d taken my own kidneys for granted and probably needed the pair to pull double-duty as a pricey biologic made its way, drip by drip, from the IV bag into my bloodstream.
The second time I was unsuspectingly shoved into having a new appreciation for the renal system was when a National Institutes of Health researcher told me he saw a nonobstructive kidney stone on one of my CT scans. Drink more water, he said as I nursed my third coffee of the day. I assured myself: Maybe it’ll just stay put and leave me alone. So far, it has. But I don’t trust it.
I know it shouldn’t have taken a heartbreaking/heartwarming story or the threat of pain reported to be worse than childbirth to make me give my kidneys the kudos they deserve. But, since then, I’ve done my kidney homework.
Here are a few tidbits about kidney history for the curious among you:
- While preparing their dead for mummification, ancient Egyptians removed all the organs — except the heart and kidneys. Apparently there’s some debate about why this was the case, with some experts arguing that the kidneys held a special position in the pantheon of internal parts and others arguing that they were simply hard for the embalmers to access.
- Richard Bright first described chronic kidney disease in 1827 in a book informed by autopsies he’d conducted. The book was illustrated by a portrait artist who — while probably in the autopsy room — painted the diseased organs in watercolor. The artist’s father is said to have then engraved or etched the images and then hired someone to hand-color the illustrations on the pages. At the time, the medical community called the condition Bright’s disease. (Also roaming the halls of Guy’s Hospital in London were Thomas Addison and Thomas Hodgkin, discoverers of Addison’s disease and Hodgkin's lymphoma, respectively.) As more was learned about chronic renal diseases, however, the eponym lost favor.
- Willem Johan Kolff, a Dutch physician, invented the first external artificial kidney during World War II. (Actually, Kolff is regarded as the father of artificial organs for having also contributed to the development of a heart–lung machine and artificial heart once he moved to the U.S.) The hemodialysis machines that followed Kolff’s creation in subsequent decades enabled patients to choose their points of care. The first dialysis clinic opened in the early 1960s, but just a decade later almost half of patients were using at-home machines. Today, in quite a turnaround, about 90 percent of patients go to dialysis centers. Meanwhile, researchers are making meaningful progress on developing an implantable artificial kidney.
I hope you’ve enjoyed this edition of “Angela Learns Stuff and Shares It with Readers.”
Now, I’m pleased to present below a collection, curated and summarized by science communicator Jonathan Griffin, of kidney stories and research in observance of this National Kidney Month.
Why do kidney disease and heart failure correlate?
People with chronic kidney disease are at unusually high risk of developing cardiovascular disease; in fact, a patient with nondialysis kidney disease is more likely to die of heart failure than to develop end-stage kidney failure. Researchers still are trying to figure out how chronic kidney disease is linked to cardiovascular disease and how best to prevent it. In a study published in the Journal of Lipid Research, German and Austrian research teams undertook a detailed longitudinal study of patients with chronic kidney disease who were not on dialysis.
New target for kidney fibrosis
Protein kinase Cα, or PKCα, is closely associated with a protein that has been implicated in kidney fibrosis, but what role PKCα plays in the development of this disease has been unclear. By blocking PKCα signaling in cells and mice with fibrotic kidneys, researchers found that the enzyme contributes to kidney fibrosis by inducing autophagy, a process wherein cells degrade their own contents. The authors suggest that a drug that inhibits PKCα might help patients with chronic kidney diseases. These findings were reported in the Journal of Biological Chemistry.
A multitalented drug
Autosomal dominant polycystic kidney disease, or ADPKD, is characterized by large cysts that can lead to organ failure. Previous research has suggested that a key protein in the lung disease cystic fibrosis is also central in the pathways that lead to cyst growth in ADPKD. In a study published in the Journal of Biological Chemistry, researchers injected a cystic fibrosis into mouse and cell models of the kidney disease. The drug shrunk cysts in both cases.
Turning back the clock on kidney disease
Kidney function degrades as we age, but this process can be slowed by calorie-restricted diets. To find out how diet can stave off the effects of aging, researchers studied protein levels in the kidneys of mice fed a caloric-restricted diet. Their report in the Journal of Biological Chemistry shows that receptor proteins FXR and TGR5, which are decreased in the aging kidney, were restored with caloric restriction. In addition, the researchers fed mice a molecule that behaves similarly to both FXR and TGR5 and saw that age-related detriments in the kidneys were reversed.
Inflammation packs on kidney fat
Kidney damage over long periods can lead to chronic kidney disease, or CKD, which disrupts the body’s ability to filter out waste. Obesity increases risk for CKD. Research has shown that inflammation promotes fat deposition on other organs, so a team researchers investigated whether this was the case for kidneys. In their study, published in the Journal of Lipid Research, mice on a high-fat diet with chronic inflammation developed lesions and accumulated lipids in the kidneys. These inflammatory effects were avoided in kidney cells by silencing the fatty acid transporter CD36, which the authors suggest could be a promising target for CKD therapy.
Cancer treatment causes collateral damage to the kidney
Cisplatin is widely used to treat many different types of cancer, but one known complication is acute kidney injury, or AKI, which can result in loss of kidney function. Administration of cisplatin increases waxy lipids known as ceramides in the kidney but it has been unclear whether these lipids contribute to AKI. In a study published in the Journal of Lipid Research, researchers prevented ceramides from being metabolized into glucosylceramides in mice, which raised the ceramide levels and increased the severity of cisplatin-induced AKI. This finding highlights the role of ceramides in the development of AKI in response to cisplatin.
How a mutant enzyme contributes to kidney cancer
SETD2, an enzyme involved in DNA methylation, is often mutated in clear cell renal carcinoma, or ccRCC, but exactly how SETD2 influences the development of the kidney cancer has not been determined. Researchers at the University of California, Riverside used CRISPR/Cas-9 technology to shed light on the role of this enzyme, removing it from kidney cells and then analyzed changes in gene transcription and protein expression. They found that loss of SETD2 repressed DNA repair, altered cell metabolism, activated cancer genes and disrupted the cell cycle, all of which create an environment conducive to tumor growth. Their study was published in the journal Molecular & Cellular Proteomics.
Tracing damage pathways in diabetic kidney disease
Diabetic kidney disease is the most common cause of kidney failure and can occur as a complication of both Type I and Type II diabetes. In a paper published in the journal of Molecular & Cellular Proteomics, researchers reported a link between the proteomic changes caused by high levels of male sex hormones and impaired energy metabolism in diabetic kidney disease.
Enjoy reading ASBMB Today?
Become a member to receive the print edition monthly and the digital edition weekly.Learn more
Get the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
The gene editing treatment from Vertex Pharmaceuticals and CRISPR Therapeutics is the first of its kind
Scientists agree that eons ago, a bacterium took up residence inside another cell and became its powerhouse, the mitochondrion. But there are competing theories about the birth of other organelles such as the nucleus and endoplasmic reticulum.